Welcome to RESTEM. We are a leading clinical-stage biopharmaceutical company focused on the discovery and development of patient-specific, as well as off-the-shelf and ready-to-use, next-generation cell therapies that are designed to activate and enhance a patient’s own immune system. Our therapies are designed to enable the treatment of a broad range of disabling diseases that improve patient outcomes, as well as overall health and wellness for patients around the world.
RESTEM’s cell therapy platform technology consists of two programs, our umbilical cord lining stem cells (ULSCs), and our natural killer cell (NK) therapeutics. Moreover, we are also developing next-generation cell therapy derivatives based on these two platforms.